Recombinant peptide drugs represent a promising frontier in the treatment of pancreatic cancer, leveraging the specificity and efficacy of engineered peptides to target cancer cells. Alfa Cytology offers a comprehensive recombinant peptide development service aimed at pioneering novel therapeutic options for pancreatic cancer.
Introduction to Recombinant Peptide
Recombinant peptides are engineered sequences of amino acids produced by recombinant DNA technology. This involves inserting DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells, and then purifying the peptide from it. These recombinant peptides are characterized by their ability to be tailored to specific biological functions, with a high degree of specificity and affinity for the target. High purity recombinant peptide synthesis allows the mapping of antibody and enzyme binding sites, epitope-specific antibody development, and the development of novel small therapeutic drug agents and vaccines.
Fig. 1 Production of peptides using DNA recombinant synthesis. (Heymich, ML, 2021)
Our Services
By integrating cutting-edge technologies and extensive expertise, Alfa Cytology provides one-stop recombinant peptide development solutions, including comprehensive services for gene synthesis, peptide expression, purification, characterization and optimization, ensuring a seamless and efficient development process.
Workflow of Recombinant Peptides Construction
Gene
Design
Customized genes encoding the target peptide sequence are designed using optimized codon usage.
Vector Construction
The designed gene is cloned into suitable expression vectors, such as bacterial, yeast, or mammalian vectors
Host Cell Transformation
The recombinant vector containing the peptide gene is introduced into host cells for expression.
Peptide Expression & Purification
The host cells are cultured under controlled conditions to induce peptide expression, followed by purification.
Characterization & Validation
The purified peptide undergoes comprehensive characterization and functional validation.
Selectable Expression Vectors
The selection of appropriate expression vectors is crucial for the successful production of recombinant peptides. Alfa Cytology utilizes a variety of expression systems tailored to meet the specific needs of each project. These vectors facilitate high-yield expression, proper folding, and post-translational modifications of peptides, ensuring optimal functionality and stability.
Bacterial Vectors
High expression levels, cost-effective production, and rapid growth rates. Suitable for initial screening and large-scale peptide production.
Examples: pET series vectors (e.g., pET-21a, pET-28a), pGEX vectors.
Yeast Vectors
Ability to perform eukaryotic-like post-translational modifications, ease of genetic manipulation, and scalable fermentation processes.
Examples: pYES2 vector for Saccharomyces cerevisiae, pPICZ vector for Pichia pastoris.
Mammalian Vectors
Precise post-translational modifications, proper folding of complex peptides, and suitable for producing biologically active peptides with therapeutic potential.
Examples: pcDNA3.1 vector, pEF1α vector, pCMV vector.
Insect Vectors
Insect cell expression systems can be used to produce biologically active peptides that require complex modifications and correct folding.
Examples: pFastBac, pAcGP67.
Advantages of Our Recombinant Peptide Technology
- Targeted Specificity: Recombinant peptides can be designed to specifically target markers on pancreatic cancer cells, minimizing off-target effects.
- Low Immunogenicity: Engineered peptides often exhibit reduced immunogenicity, enhancing their safety profile for therapeutic use.
- Flexible Design: Peptides can be customized for various therapeutic strategies, including inhibition of cancer cell growth, induction of apoptosis, and modulation of the tumor microenvironment.
- Enhanced Stability: Optimized peptide sequences and structural modifications improve stability, ensuring sustained efficacy in physiological conditions.
Alfa Cytology's recombinant peptide development service is dedicated to advancing pancreatic cancer therapeutic research through innovative and precise peptide engineering. The service provides comprehensive solutions from gene synthesis to preclinical testing to ensure efficient development of therapeutic peptides. If you are looking for expert support and collaboration in recombinant peptide development, please do not hesitate to contact us.
Reference
- Heymich, M L. The generation of antimicrobial peptides from plants for the preservation of food. Doctoral dissertation, Friedrich-Alexander-Universitaet Erlangen-Nuernberg (Germany). 2021.
